NO973343L - Antiinflammatoriske öyedråper - Google Patents

Antiinflammatoriske öyedråper Download PDF

Info

Publication number: NO973343L
Authority: NO; Norway
Prior art keywords: eye drops; formulation; exception; repeated; dfna
Prior art date: 1995-01-20

Application number

NO973343A

Other languages

English (en)

Norwegian (no)

Other versions

NO973343D0 (no

Inventor

Masanobu Takeuchi

Hiroki Maruyama

Hiroe Suzuki

Touru Oguma

Makoto Maede

Original Assignee

Wakamoto Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-20

Filing date

1997-07-18

Publication date

1997-09-19

1997-07-18 Application filed by Wakamoto Pharma Co Ltd filed Critical Wakamoto Pharma Co Ltd

1997-07-18 Publication of NO973343D0 publication Critical patent/NO973343D0/no

1997-09-19 Publication of NO973343L publication Critical patent/NO973343L/no

Links

239000003889 eye drop Substances 0.000 title claims abstract description 79
229940012356 eye drops Drugs 0.000 title claims abstract description 76
230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 12
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 22
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 22
229960001950 benzethonium chloride Drugs 0.000 claims abstract description 12
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims abstract description 12
229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 11
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 11
229960001193 diclofenac sodium Drugs 0.000 claims abstract description 10
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims abstract description 10
229920000858 Cyclodextrin Polymers 0.000 claims abstract description 9
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 5
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims abstract 2
229940080345 gamma-cyclodextrin Drugs 0.000 claims abstract 2
229920001353 Dextrin Polymers 0.000 claims 1
239000004375 Dextrin Substances 0.000 claims 1
235000019425 dextrin Nutrition 0.000 claims 1
239000000203 mixture Substances 0.000 description 67
238000009472 formulation Methods 0.000 description 66
238000000034 method Methods 0.000 description 34
230000007794 irritation Effects 0.000 description 20
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 18
230000000694 effects Effects 0.000 description 18
238000002360 preparation method Methods 0.000 description 13
238000003860 storage Methods 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000000825 pharmaceutical preparation Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000002198 insoluble material Substances 0.000 description 7
239000003755 preservative agent Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 5
239000006172 buffering agent Substances 0.000 description 5
239000008213 purified water Substances 0.000 description 5
235000002639 sodium chloride Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000035807 sensation Effects 0.000 description 4
208000002177 Cataract Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
229910021538 borax Inorganic materials 0.000 description 3
239000004327 boric acid Substances 0.000 description 3
235000010338 boric acid Nutrition 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000002997 ophthalmic solution Substances 0.000 description 3
229940054534 ophthalmic solution Drugs 0.000 description 3
235000010339 sodium tetraborate Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 3
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
208000009137 Behcet syndrome Diseases 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
206010010741 Conjunctivitis Diseases 0.000 description 2
206010015084 Episcleritis Diseases 0.000 description 2
206010015958 Eye pain Diseases 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
208000006550 Mydriasis Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
206010038848 Retinal detachment Diseases 0.000 description 2
206010039705 Scleritis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000004350 Strabismus Diseases 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
229940043377 alpha-cyclodextrin Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
UHDGCWIWMRVCDJ-XVFCMESISA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 2
239000006196 drop Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
238000001914 filtration Methods 0.000 description 2
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
208000008025 hordeolum Diseases 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000000622 irritating effect Effects 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
159000000003 magnesium salts Chemical class 0.000 description 2
239000000463 material Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000003002 pH adjusting agent Substances 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
201000004768 pinguecula Diseases 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
230000004264 retinal detachment Effects 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
206010006784 Burning sensation Diseases 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
239000001116 FEMA 4028 Substances 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
229920003081 Povidone K 30 Polymers 0.000 description 1
229920003082 Povidone K 90 Polymers 0.000 description 1
-1 Y-CyD Chemical compound 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 1
229960004853 betadex Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000003560 epithelium corneal Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
229960004369 flufenamic acid Drugs 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000002911 mydriatic effect Effects 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
231100001254 ocular irritant Toxicity 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940037001 sodium edetate Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO973343A 1995-01-20 1997-07-18 Antiinflammatoriske öyedråper NO973343L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2448595		1995-01-20
PCT/JP1995/002680 WO1996022088A1 (fr)	1995-01-20	1995-12-26	Gouttes oculaires anti-inflammatoires

Publications (2)

Publication Number	Publication Date
NO973343D0 NO973343D0 (no)	1997-07-18
NO973343L true NO973343L (no)	1997-09-19

Family

ID=26361998

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO973343A NO973343L (no)	1995-01-20	1997-07-18	Antiinflammatoriske öyedråper

Country Status (11)

Country	Link
US (1)	US5929115A (fr)
EP (1)	EP0807434B1 (fr)
JP (1)	JP3672569B2 (fr)
AT (1)	ATE215821T1 (fr)
AU (1)	AU690794B2 (fr)
CA (1)	CA2210749C (fr)
DE (1)	DE69526369T2 (fr)
FI (1)	FI973060A7 (fr)
NO (1)	NO973343L (fr)
RU (1)	RU2136252C1 (fr)
WO (1)	WO1996022088A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT877600E (pt) *	1996-08-09	2004-02-27	Alcon Mfg Ltd	Sistemas conservantes para composicoes farmaceuticas contendo ciclodextrinas
RU2156128C1 (ru) *	2000-01-05	2000-09-20	Гапонюк Петр Яковлевич	Глазные капли для лечения воспалительных заболеваний глаз с аллергическими проявлениями
JP3450805B2 (ja) *	2000-08-08	2003-09-29	わかもと製薬株式会社	水性医薬組成物
RU2197246C2 (ru) *	2000-10-05	2003-01-27	Новикова Людмила Серафимовна	Глазной препарат и способ его получения
RU2193403C1 (ru) *	2001-05-23	2002-11-27	Московский научно-исследовательский институт глазных болезней им. Гельмгольца	Глазные капли для лечения аллергических конъюнктивитов и кератоконъюнктивитов
RU2216331C1 (ru) *	2002-02-26	2003-11-20	Уфимский научно-исследовательский институт глазных болезней	Глазные капли
US20040013729A1 (en) *	2002-07-18	2004-01-22	Buono Lawrence M.	Single-drop multiple-agent composition for topical delivery to the eye
KR20050092429A (ko) *	2003-01-22	2005-09-21	니찌방 가부시기가이샤	안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
JP4947977B2 (ja) *	2003-10-31	2012-06-06	わかもと製薬株式会社	可逆性熱ゲル化水性組成物
PT1905453E (pt) *	2005-07-13	2012-12-04	Santen Pharmaceutical Co Ltd	Composição conservante para utilização oftálmica
US20070232567A1 (en) *	2006-03-28	2007-10-04	Curtis Wright	Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
CN101410123A (zh)	2006-03-28	2009-04-15	杰佛林制药公司	低剂量的双氯芬酸和β－环糊精的制剂
BR112013034051A2 (pt) *	2011-06-29	2019-09-24	Allergan Inc	formulações de macrogol 15 hidroxiestearato
WO2013149075A1 (fr) *	2012-03-29	2013-10-03	Cxl Ophthalmics, Llc	Compositions et procédés de traitement ou de prévention de maladies associées au stress oxydatif
EP3452093B1 (fr) *	2016-05-06	2021-04-28	Sacsh Corp.	Compositions ophtalmiques
US11110073B2 (en) *	2017-03-24	2021-09-07	Cadila Healthcare Limited	Storage stable aqueous injectable solution comprising diclofenac
CA3074326A1 (fr) *	2017-09-01	2019-03-07	Murray & Poole Enterprises, Ltd.	Procedes et compositions pour le traitement d'affections ophtalmiques
US11707443B2 (en)	2019-09-26	2023-07-25	Rk Pharma Inc.	Storage stable aqueous parenteral solutions comprising diclofenac
WO2022156371A1 (fr) *	2021-01-22	2022-07-28	成都瑞沐生物医药科技有限公司	Support ou substance auxiliaire de préparation ophtalmique, son procédé de préparation et son application

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58174309A (ja) *	1982-04-06	1983-10-13	Wakamoto Pharmaceut Co Ltd	消炎点眼剤
JPS58174310A (ja) *	1982-04-06	1983-10-13	Wakamoto Pharmaceut Co Ltd	抗炎症点眼剤
JPS5929616A (ja) *	1982-08-10	1984-02-16	Kaken Pharmaceut Co Ltd	抗炎症眼科用液剤およびその製法
JPS60136516A (ja) *	1983-12-26	1985-07-20	Kaken Pharmaceut Co Ltd	抗炎症眼科用液剤およびその製法
DE3612537C1 (de) *	1986-04-14	1987-07-16	Dispersa Ag	Arzneimittel zur Behandlung von Entzuendungen im Auge
JPS6416728A (en) *	1987-07-07	1989-01-20	Santen Pharmaceutical Co Ltd	Aqueous preparation
DK174702B1 (da) *	1987-09-11	2003-09-29	Syntex Llc	Konserveringssystem til ophthalmiske formuleringer
US4960799A (en) *	1988-09-13	1990-10-02	Ciba-Geigy Corporation	Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
TW200402B (fr) *	1990-08-13	1993-02-21	Senju Pharma Co
JPH0616547A (ja) *	1992-07-01	1994-01-25	Wakamoto Pharmaceut Co Ltd	消炎点眼剤
ES2079994B1 (es) *	1992-10-07	1996-08-01	Cusi Lab	Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
AU5599594A (en) *	1992-11-16	1994-06-08	Ciba-Geigy Ag	Polyvinyl alcohol/borate ophthalmic drug delivery system
RU2049467C1 (ru) *	1993-04-16	1995-12-10	Научно-исследовательская фирма "Ультрасан"	Антибактериальный, противовоспалительный препарат
RU2062079C1 (ru) *	1993-08-25	1996-06-20	Уфимский научно-исследовательский институт глазных болезней	Глазные капли
US5576311A (en) *	1994-11-30	1996-11-19	Pharmos Corporation	Cyclodextrins as suspending agents for pharmaceutical suspensions

1995
- 1995-12-26 AU AU43156/96A patent/AU690794B2/en not_active Ceased
- 1995-12-26 WO PCT/JP1995/002680 patent/WO1996022088A1/fr not_active Ceased
- 1995-12-26 RU RU97113691/14A patent/RU2136252C1/ru not_active IP Right Cessation
- 1995-12-26 FI FI973060A patent/FI973060A7/fi unknown
- 1995-12-26 EP EP95941885A patent/EP0807434B1/fr not_active Expired - Lifetime
- 1995-12-26 CA CA002210749A patent/CA2210749C/fr not_active Expired - Fee Related
- 1995-12-26 US US08/875,101 patent/US5929115A/en not_active Expired - Fee Related
- 1995-12-26 DE DE69526369T patent/DE69526369T2/de not_active Expired - Fee Related
- 1995-12-26 AT AT95941885T patent/ATE215821T1/de not_active IP Right Cessation
- 1995-12-26 JP JP52215596A patent/JP3672569B2/ja not_active Expired - Fee Related
1997
- 1997-07-18 NO NO973343A patent/NO973343L/no unknown

Also Published As

Publication number	Publication date
AU690794B2 (en)	1998-04-30
EP0807434A1 (fr)	1997-11-19
DE69526369D1 (de)	2002-05-16
DE69526369T2 (de)	2002-11-07
ATE215821T1 (de)	2002-04-15
CA2210749A1 (fr)	1996-07-25
NO973343D0 (no)	1997-07-18
RU2136252C1 (ru)	1999-09-10
FI973060L (fi)	1997-07-18
AU4315696A (en)	1996-08-07
CA2210749C (fr)	2001-04-10
EP0807434A4 (fr)	1998-04-22
FI973060A0 (fi)	1997-07-18
US5929115A (en)	1999-07-27
WO1996022088A1 (fr)	1996-07-25
FI973060A7 (fi)	1997-07-18
EP0807434B1 (fr)	2002-04-10
JP3672569B2 (ja)	2005-07-20

Publication	Publication Date	Title
NO973343L (no)	1997-09-19	Antiinflammatoriske öyedråper
TWI489997B (zh)	2015-07-01	含有硼酸－多元醇錯合物之水性藥學組成物
HU199072B (en)	1990-01-29	Antimicrobal conserving composition and process for production of compositions for oculist purpuses
JP6888754B2 (ja)	2021-06-16	インサイチュでゲルを形成する医薬製剤
TW200402B (fr)	1993-02-21
JP2017206547A (ja)	2017-11-24	眼科用組成物
JPS58126810A (ja)	1983-07-28	抗炎症眼科用液剤およびその製法
NO173212B (no)	1993-08-09	Fremgangsmaate for fremstilling av et oftalmologisk preparat
JPWO1996022088A1 (ja)	1998-02-24	抗炎症点眼剤
CN101977630B (zh)	2012-11-21	眼药组合物
BRPI0416123B1 (pt)	2018-11-21	composição antiinflamatória e composição antiinfecciosa para uso oftálmico ou otolaringológico e método para tratar a dita inflamação e infecção
WO2011018800A2 (fr)	2011-02-17	Nouvelle solution formant un gel in situ pour ladministration de médicaments par voie oculaire
JP4773721B2 (ja)	2011-09-14	第四級化アンモニウムシクロデキストリン化合物
JP2001508035A (ja)	2001-06-19	炭酸脱水酵素阻害薬及びキサンタンガムを含有する眼科用組成物
JPH0616547A (ja)	1994-01-25	消炎点眼剤
JP4966854B2 (ja)	2012-07-04	キサンタンガムおよびテルペノイドを含有する点眼剤
WO2017151664A1 (fr)	2017-09-08	Compositions pharmaceutiques pour l'administration d'un médicament de type fluoroquinolone
KR20200080493A (ko)	2020-07-07	효과 지속성 점안제 조성물
AU2008273874A1 (en)	2009-01-15	Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins
WO2002040028A1 (fr)	2002-05-23	Gouttes pour les yeux en gel antibacterien
KR100261585B1 (ko)	2000-07-15	항염증점안제
JPS5929616A (ja)	1984-02-16	抗炎症眼科用液剤およびその製法
US8679511B2 (en)	2014-03-25	In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
KR0159640B1 (ko)	1998-12-01	도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형
KR20180077719A (ko)	2018-07-09	지속성 점안제 조성물